Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Latuda | lurasidone | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
Latuda | Lurasidone | Schizophrenia | Do not list | Complete | ||
Latuda | Lurasidone | Schizophrenia | List with criteria/condition | Complete | ||
Zepzelca | lurbinectedin | metastatic small cell lung cancer (SCLC) | Do not reimburse | Complete | ||
Reblozyl | luspatercept | beta-thalassemia associated anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Reblozyl | luspatercept | Myelodysplastic syndromes-associated anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Lutathera | Lutetium Lu 177 dotatate | Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | Reimburse with clinical criteria and/or conditions | Complete | ||
Lutathera | lutetium oxodotreotide | Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) | Reimburse with clinical criteria and/or conditions | Complete | ||
Pluvicto | lutetium vipivotide tetraxetan | Metastatic castration-resistant prostate cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Opsumit | Macitentan | Pulmonary arterial hypertension | List with clinical criteria and/or conditions | Complete |